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Malaria is a major threat to world health. The identifi-
cation of parasite targets for drug development is
a priority and parasitic protein kinases suggest them-
selves as suitable targets as many display profound
structural and functional divergences from their
host counterparts. In this paper, we describe the
structure of the orphan protein kinase, Plasmodium
falciparumprotein kinase 7 (PFPK7). SeveralPlasmo-
dium protein kinases contain extensive insertions,
and the structure of PFPK7 reveals how these may
be accommodated as excursions from the canonical
eukaryotic protein kinase fold. The constitutively
active conformation of PFPK7 is stabilized by a struc-
tural motif in which the role of the conserved phos-
phorylated residue that assists in structuring the
activation loop of many protein kinases is played by
an arginine residue. We identify two series of PFPK7
ATP-competitive inhibitors and suggest further de-
velopments for the design of selective and potent
PFPK7 lead compounds as potential antimalarials.
INTRODUCTION
Plasmodium falciparum, the most virulent species of human ma-
laria parasites, is responsible for the most severe forms of the
disease and causes 1–2 million deaths annually, predominantly
among children from Sub-Saharan Africa. The lack of a licensed
vaccine and the widespread resistance of P. falciparum against
most available antimalarials have created an urgent need for
novel control agents targeting different biochemical pathways
(Ridley, 2002; Renslo and McKerrow, 2006). ‘‘Piggy backing’’
the development of new compounds on advances being made
for the treatment of other diseases that share an underlying228 Structure 16, 228–238, February 2008 ª2008 Elsevier Ltd All rmolecular mechanism is a potential strategy to identify new
antimalarials (Nwaka and Hudson, 2006). In this context, protein
kinases have been proposed as targets (Doerig et al., 2005) as
aberrant protein kinase activity contributes to the development
of a number of clinical conditions (Sausville et al., 2003; Sweeney
and Firestein, 2004; Ventura and Nebreda, 2006; Peifer et al.,
2006), and a number of protein kinase inhibitors are in the clinic
or in late-stage clinical trials (Ventura and Nebreda, 2006). In
addition, the results of both high-throughput screening and
structure-led approaches to the design of ATP-competitive
protein kinase inhibitors have provided an understanding of
how potency against a particular protein kinase can be derived
and, increasingly, a greater understanding of inhibitor selectivity
(Fischer, 2004; Vieth et al., 2004; Noble et al., 2004).
The P. falciparum kinome contains 65 eukaryotic-like protein
kinases (ePKs) (Ward et al., 2004; Anamika et al., 2005) that
have temporal and spatial patterns of expression suggestive of
specific roles in execution of the P. falciparum lifecycle in both
human andAnopheles hosts. Many members of theP. falciparum
kinome have been classified into familieswhose members inother
eukaryotes play important roles in regulating cell growth and divi-
sion. There are also P. falciparum ‘‘orphan’’ kinases, which by
sequence analysis, cannot be ascribed to a recognizable eukary-
otic protein kinase family. Members of both these classes are
potential targets for drug design: the first because of their
predicted roles in regulating the complex P. falciparum lifestyle,
and the second because they promise to offer P. falciparum-
specific drug targets (Pattanaik et al., 2002; Doerig et al., 2005).
Plasmodium falciparum protein kinase 7 (PFPK7) (Dorin et al.,
2005) (PlasmoDB identifier PFB0605w) is classified as an ‘‘or-
phan’’ kinase with no human homolog (Ward et al., 2004) and
can autophosphorylate and phosphorylate myelin basic protein
and, to a lesser extent, histone H2A and b-casein (Dorin et al.,
2005). The two closest human homologs by overall sequence
identity are dual specificity mitogen activated protein (MAP) ki-
nase kinase 3 (MAP2K3, Swiss-Prot entry P46734) (Figure 1A)
and serine/threonine-protein kinase 6 (AURORA-A, Swiss-Protights reserved
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The Structure of PFPK7entry O14965) with 33% and 26% sequence identity, respec-
tively. However, despite being the most MAP kinase kinase
(MAP2K)-like sequence in the P. falciparum genome, PFPK7
does not display MAP2K activity and is not a MAP2K ortholog
(Dorin et al., 2005). Disruption of the PFPK7 gene suggests
that PFPK7 is involved in a pathway regulating cell proliferation
and development as P. falciparum clones in which the PFPK7
locus has been inactivated are viable, but their asexual growth
rate is about half that observed in wild-type parasites (Dorin-
Semblat et al., 2008). This phenotype suggests that PFPK7 inac-
tivation through chemical inhibition would be expected to slow
parasite growth and, hence, decrease the virulence of infection.
In this paper, we describe the structure of PFPK7 and charac-
terize its biochemical activity. The integrity of the PFPK7 active
site is maintained by a novel twist to a structural motif that is
conserved among higher eukaryotic protein kinases. Using
peptide microarray analysis, we have identified PFPK7 substrate
sequence preferences that surround the phosphotransfer
residue. Furthermore, we have employed a protein thermal stabil-
ity shift assay (Bullock et al., 2005; Matulis et al., 2005) to identify
two series of ATP-competitive inhibitors that inhibit PFPK7 activ-
ity in the micromolar range. Both compound series were found
to inhibit asexual growth of P. falciparum in blood-stage cultures.
Structure determination of selected compounds bound to PFPK7
has revealed the molecular interactions that mediate specific in-
hibitor binding. These inhibitors represent hits for the design of
selective and potent PFPK7 inhibitors.
RESULTS
The Structure of PFPK7
PFPK7 is 343 residues in length and encodes little more than the
protein kinase catalytic domain. As previously observed in other
protein kinase structures, PFPK7 adopts a bilobate structure
(Figure 1B and Movie S1, see the Supplemental Data available
with this article online). The N-terminal lobe is composed of
a twisted antiparallel b sheet and two a helices, the larger
of which forms the back of the ATP-binding site cleft. This
helix encoded by PFPK7 residues 80–93 is called the C helix
(Knighton et al., 1991b) and includes an essential glutamate res-
idue (PFPK7 Glu88) that is conserved within the protein kinase
family. The larger C-terminal lobe is predominantly a helical.
PFPK7 is bound to adenylyl imidodiphosphate (AMPPNP, a non-
hydrolysable ATP analog) and is in its active conformation so that
the conserved residues that compose the active site are poised
for catalysis (Figure S1). The adenine ring of ATP is buried within
the active site cleft and makes two hydrogen bonds with PFPK7:
one between N1 and the backbone amide group of Met120
within the hinge sequence and the other between the N6 NH2
and the backbone carbonyl moiety of Glu118. The ribose 20
and 30 hydroxyl groups form hydrogen bonds with the side chain
of Asp123 and the backbone carbonyl group of Ser176,
respectively, and the a and b phosphate groups are coordinated
through a network of salt bridge interactions to Lys55 and Glu88.
This network includes an Mn2+ ion that is bound in octahedral
coordination and chelates the a, b, and g phosphates. Notably,
there is a direct electrostatic interaction between Asn40 from
the glycine-rich loop and the b phosphate moiety. In most protein
kinases, the conserved glycine-rich loop that connects b1 to b2Structure 16,conforms to the consensus sequence GXGXfG (where X repre-
sents any amino acid and f a hydrophobic residue), but in the
PFPK7 sequence, this has diverged to NQGKFN. As previously
observed in other active protein kinases, this motif in PFPK7
forms a lid above the catalytic site and adopts an open confor-
mation (Tsigelny et al., 1999). The PQS server at the EBI identifies
a PFPK7 dimer within the crystal lattice with a buried surface
area of 2954 A˚2. However, PFPK7 behaves as a monomer in
solution as judged by analytical size-exclusion chromatography
(results not shown).
P. falciparum proteins are frequently characterized by having
long low-complexity insertions compared to their homologs in
other eukaryotic species (Pizzi and Frontali, 2001). In compari-
son with other protein kinases, PFPK7 has two notable additional
sequences of 17 (called insertion 2, I2) and 19 (called I4) residues
respectively starting at Glu63 and Asp270 (Figure 1B). The extra
sequence within the N-terminal fold forms an extended b-hairpin
that is stabilized through crystal contacts and, as a result, is well
defined in the electron density map despite having no contact
with other parts of the PFPK7 structure. A representation of the
PFPK7 surface colored by electrostatic potential reveals that
this extended loop has a peppered distribution of positively
and negatively charged patches (Figure 1C). In contrast, a part
of the I4 sequence associates with the PFPK7 core fold. Resi-
dues 270–279 at the start of I4 are supported by weak electron
density and fold back along a portion of the structure that
corresponds to an additional short insertion (called I3, residues
134–140) (Figure 1B). These residues are solvent exposed and
not engaged in crystal contacts. However, the sequence of
insertion I4 from residue 280 to 287 is disordered and the quality
of the electron density map was such that this sequence could
not be built.
The structure of PFPK7 was compared to the database of
deposited protein kinase structures (Krissinel and Henrick,
2004) and was found to be similar to TAO2 kinase, a MAPKKK
(PDB ID: 1U5R) (Zhou et al., 2004) (Figures 1A and 2A and Movie
S2). Both structures contain an additional short helix within the
N-terminal domain that in PFPK7 starts with the initiating methi-
onine and extends over 1.25 helical turns against the back of
the PFPK7 active site above the C helix (Figure 1B). Met1, Ile4,
Leu5, and Tyr8 form a hydrophobic surface that packs against
Leu11, Leu89, Cys103, and Ile106 (Figure 2A). The position of
this short helix suggests that it may assist in stabilizing the C helix
in its catalytically active conformation. An overlay of PFPK7,
TAO2K, and CDK2-cyclin A (Figure 2) reveals the similar location
in each structure of a helical segment that packs against the
C helix. Notably, in the CDK2-cyclin A structure, the helix
originates from cyclin A. Following this helix, the PFPK7 se-
quence digresses out into another extended b hairpin (insert I1)
before turning back into the kinase fold at the start of b1
(Figure 1B).
A phosphorylated serine or threonine residue, or alternatively
a negatively charged amino acid residue, is a conserved element
in the activation loop structures of active protein kinases (PFPK7
residues Asp190-Glu215 between and including the conserved
DFG and APE motifs) (Hanks and Hunter, 1995). This moiety
was first observed in cAMP-dependent protein kinase (Knighton
et al., 1991a) where it acts as a hub to which residues from the C
helix and the catalytic and activation loops bind (Huse and228–238, February 2008 ª2008 Elsevier Ltd All rights reserved 229
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The Structure of PFPK7Kuriyan, 2002). As a result, the activation loop is anchored close
to the interface between N- and C-terminal kinase lobes so as to
form an extended surface that recognizes the protein substrate
at residues around the site of phospho-transfer (Knighton
et al., 1991b; Brown et al., 1999). The PFPK7 structure reveals
that this structural motif is conserved in PFPK7, but uniquely
the negatively charged residue is replaced by an arginine
(Arg206), and as a result, its ligands offer compensating nega-
tively charged groups (Figure 2B). These include the side chains
of Asp84 (from the start of the C helix) and of Glu193 and Glu195
that immediately follow the DFG motif at the start of the activa-
tion loop. Thus, the principle of enzymatic activation through
an electrostatic interaction involving a residue in the activation
loop is maintained, but this is, to our knowledge, the first exam-
ple where this residue is positively charged. This illustrates the
divergence of this enzyme relative to protein kinases of higher
eukaryotes.
PFPK7 Peptide Substrate Phosphorylation
An arrayed peptide library of known protein kinase substrate
sequences was used to identify a consensus peptide substrate
sequence for PFPK7 (details provided in Table S1 and in Supple-
mental Data). This sequence (r-R-R/K-K/R-S/T-P-K/R-K-R) has
a strong preference for substrates with positively charged amino
acids at positions P4, P3, and P2 and P+2, P+3, and P+4. At
position P1, though a lysine residue is favored, substrate
peptides also contained alanine and proline residues. At P+1,
though a proline was the most abundant amino acid, lysine
and serine were also favored. In support of this sequence prefer-
ence, the substrate binding cleft is characterized by an overall
negative charge (Figure 1C). Superimposing the structures of
the PKA peptide inhibitor PKI extracted from the structure of
a PKA/PKI complex (Knighton et al., 1991b) and PFPK7 shows
that a PFPK7 substrate peptide at residues beyond P+3 would
contact the extended PFPK7 I2 loop, suggesting that it may con-
tribute to PFPK7 substrate selectivity. Proline-directed kinases
create an unusually shaped pocket to accept the amino acid
side chain through a residue within the activation loop adopting
unusual backbone fc angles (Brown et al., 1999). The PFPK7
activation loop has no such structure, and at the equivalent lo-cation, Gly207 is directed back into the catalytic cleft so that
a pocket is not formed and a proline side chain would not
be favorably accommodated, in agreement with the more re-
laxed sequence preference at the P+1 position identified by
the peptide microarray analysis.
PFPK7 Autophosphorylation
PFPK7 purified from E. coli cells is constitutively active, un-
dergoes autophosphorylation, and can use myelin basic protein,
P. falciparum RAB11B and, albeit less readily, histone 2A as sub-
strates (Supplemental Experimental Procedures and results not
shown). PFPK7 can autophosphorylate in trans as shown by ex-
periments in which wild-type PFPK7 is able to phosphorylate the
kinase-dead K55M PFPK7 mutant (Figure S2). Within the activa-
tion loop, there are three potential serine/threonine phosphoryla-
tion sites at Ser194, Ser205, and Thr208. However, the electron
density map did not detect phosphorylation of any of these res-
idues. Each residue was mutated to alanine, and mutants were
assayed for autophosphorylation and activity toward PFRAB11B
as a substrate (Supplemental Data and results not shown). A
threonine residue equivalent to PFPK7 Thr208 is highly con-
served within the protein kinase family (Thr201 in PKA) and it
makes an essential hydrogen bond to the catalytic base
(PFPK7 Asp172). The mutation of this residue to either an alanine
or glutamate as predicted disrupts the network of interactions
at the catalytic site and results in a loss of activity. The
PFPK7 S194A and S205A mutants displayed wild-type levels
of activity. This result strongly suggests that the activity of
wild-type PFPK7 does not result from a small amount of very
active PFPK7 phosphorylated within the activation loop in the
PFPK7 preparation. Taken together with the structural results,
this data suggests that PFPK7 is not phosphorylated within the
activation loop.
The experimental electron density maps contain an additional
strong peak associated with the side chain of Ser176 that
suggests that in some PFPK7 preparations this residue is phos-
phorylated (Figure S3A). Ser176 was mutated to both alanine
(PFPK7 S176A) and to glutamate (PFPK7 S176E) and the activ-
ities of the mutant proteins as compared to wild-type PFPK7
were determined (Figure S3). PFPK7 S176A and PFPK7 S176EFigure 1. PFPK7 Structure
(A) PFPK7 sequence alignment. The sequence of PFPK7 (top row) was aligned by SSM (Krissinel and Henrick, 2004) structural superposition with the sequences
of the most closely related structure in the PDB (rat TAO2 kinase, PDB ID: 2gcd, second row) and the most closely related human kinase structure (human PDK1,
PDB ID: 1oky, third row). The resulting alignment was used in a profile-to-sequence alignment, performed by the program CLUSTALW (Thompson et al., 1994),
with the most closely sequence-related human kinase (human MAP2K3, Uniprot accession number Q6FI23, fourth row). Residues not resolved in electron density
maps of PFPK7 (residues 280–287) or human PDK1 (residues 233–238) are highlighted in black. Regions of homology, identified by JALVIEW (Clamp et al., 2004),
are highlighted in light shades of purple. In order to identify amino acids that line the ATP-binding site, residues of PFPK7 or rat TAO2 kinase that lie within 5 A˚ of
ligands in the respective AMPPNP and ATP complexes of those structures are highlighted in gray. Secondary structural elements of PFPK7, identified by DSSP
(Kabsch and Sander, 1983), are indicated in cartoon representation beneath the alignment. Insert regions illustrated in (B) are highlighted in dark purple and are
annotated beneath the alignment. The figure was eventually prepared with JALVIEW.
(B) PFPK7 overall fold. PFPK7 is rendered in ribbon representation and color ramped from blue at the N terminus through green to red at the C terminus. AMPPNP
is drawn in ball-and-stick mode with carbon atoms pink. I2 (residues 63–79) adopts an extended b-hairpin conformation inserted into the N-terminal lobe just
before the start of the C helix. Insert I4 (residues 270–288) is also labeled. However, the structure breaks after residue 279 and starts again at 288 (located by
stars). I3 (residues 134–140) stabilizes the start of I4, and I1 forms a short b hairpin. The four insert sequences are labeled and colored dark gray. (See text
and the Movie S1 for further details.)
(C) PFPK7 molecular surface. The PFPK7 molecular surface (same view as in [B]) is colored by electrostatic potential such that blue and red correspond to
potentials of 0.2 V and 0.2 V, respectively. The view highlights the negatively charged character of the protein substrate binding site located by the superposition
of the PKI peptide extracted from the structure of a PKA/PKI peptide complex (PDB ID: 1ATP) (Knighton et al., 1991b). The PKI peptide is drawn in cyan in
ball-and-stick mode. Figures prepared with AESOP (M.N., unpublished data).
(D) PFPK7 Ca trace. Stereo pair. The structure of PFPK7 is shown with every 10th amino acid labeled at its Ca position.
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Structure
The Structure of PFPK7Figure 2. Comparison of PFPK7 with TAO2 Kinase and CDK2-Cyclin A
(A) Overlay of the PFPK7, TAO2 kinase, and CDK2-cyclin A structures. The structures of PFPK7, TAO2 kinase (PDB ID: 1U5R), and CDK2-cyclin A (PDB ID: 1JST)
were superimposed on the basis of the kinase domain. The PFPK7 structure is rendered in ribbon representation and colored gold. For clarity, only residues 12–18
of TAO2 kinase (colored purple) and helix a5 of the cyclin A N-terminal cyclin box fold (residues 288–301), colored green, are drawn. Selected residues that
contribute to the interface between the PFPK7 N-terminal and C helices are also included (see text and the Movie S2 for further details).
(B) The structure of the PFPK7 activation loop. The PFPK7 structure is rendered as a gold ribbon and selected residues are drawn in ball-and-stick mode. PFPK7
Arg206 acts as a structural hub within the activation loop to stabilize the PFPK7 structure and is liganded by Asp84 in the C helix and residues Glu193 and Glu195
at the start of the activation loop. PFPK7 is a RD kinase and Arg171 precedes the catalytic base (Asp172) (see text for further details). For comparison, the PKA
structure is also drawn with carbons in cyan to highlight the conservation of this structural motif: in PKA, phosphorylated Thr197 plays the same role as Arg206
and interacts with His84, Arg165 (equivalent to PFPK7 Arg171), and Lys 189.were still able to autophosphorylate and to phosphorylate an
exogenous substrate, although at a reduced level compared to
wild-type PFPK7. This result suggests that PFPK7 Ser176 is
not a unique site for autophosphorylation and that Ser176 phos-
phorylation may affect PFPK7 activity.
Identification of PFPK7 ATP-Competitive Inhibitors
An initial study to identify PFPK7 inhibitors by testing a diverse
set of known ATP-competitive protein kinase inhibitors failed
to identify a compound with an IC50 less than 30 mM, and most
compounds exhibited values >100 mM (Dorin et al., 2005). To
identify compounds suitable for cocrystallization studies, we
used a thermostability shift assay to screen a kinase-targeted
library of 568 compounds (Matulis et al., 2005; Bullock et al.,
2005). Compounds that induced a shift in the PFPK7 Tm of >4
C
were selected for further study and were found to belong to two
different structural classes (Table 1). 1NM-PP1 (4-Amino-1-tert-
butyl-3-(10-naphthylmethyl)pyrazolo[3,4-d ]pyrimidine) and PP2
(4-Amino-5-(4-chlorophenyl)-7-[t-butyl]pyrazolo[3,4-d]pyrimidine)
are related compounds that were identified as Src kinase in-
hibitors (Hanke et al., 1996; Bishop et al., 1999) and show
good selectivity for members of the Src family (Bain et al., 2003).
(S)-4-(6-(1-hydroxy-3-methylbutan-2-ylamino)imidazo[1,2-b]
pyridazin-3-yl)benzonitrile (K510), 3-(4-chlorophenyl)-N-(pyridin-
3-ylmethyl)pyrazolo[1,5-a]pyrimidin-5-amine, (K109), and 4-(6-
(tetrahydro-2H-pyran-4-ylamino)imidazo[1,2-b]pyridazin-3-yl)-
benzonitrile (K497), though isolated independently in the232 Structure 16, 228–238, February 2008 ª2008 Elsevier Ltd All rithermostability assay, are also closely related and originate
from a kinase-focused library (Birault et al., 2006; Harris and
Stevens, 2006). The compounds all inhibit PFPK7 activity in the
low mM range and are all substantially more potent than previ-
ously tested compounds (Dorin et al., 2005) (Table 1).
The compounds were also tested for their ability to inhibit
asexual growth of P. falciparum in blood-stage cultures (Table
1 and Figure S4). Three K-series compounds (K510, K109, and
K497) and PP2 were all potent inhibitors, with measured IC50
values in the low mM range. However, the two PP1 derivatives,
1NM-PP1 and 1NA-PP1 (4-Amino-1-tert-butyl-3-(10-naphthyl)-
pyrazolo[3,4-d]pyrimidine), were less active. Parasites lacking
PFPK7 are still able to multiply asexually in erythrocytes, albeit
at a reduced rate in comparison to wild-type (Dorin-Semblat
et al., 2008). This suggests that the in vitro effects of all five inhib-
itors might result from the inhibition of multiple P. falciparum (or
host) protein kinases. Indeed, K497 was tested against a panel of
78 kinases (University of Dundee protein kinase profiling service)
and was found to inhibit a number in the low micromolar range
(results not shown).
PFPK7-ATP-Competitive Inhibitor Complexes
To elaborate the molecular interactions between PFPK7 and
inhibitors that target the ATP binding site, the structures of com-
plexes of PFPK7 bound to K510 and to hymenialdisine were
determined. Like ATP, K510 accepts a hydrogen bond from
the backbone amide group of Met120 (Figure 3A). The planarghts reserved
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The Structure of PFPK7Table 1. Chemical Structures and IC50 Values for Selected Inhibitors against PFPK7
Inhibitor Chemical structure IC50 (Autophosphorylation, mM) GI50 (Blood Culture, mM)
K510a 6.3 2.5
K109b 4.6 1.0
K497c 4.3 1.5
1NM-PP1d >100 21
1NA-PP1e 14.9 75
PP2f n.d.g 2
a (S)-4-(6-(1-hydroxy-3-methylbutan-2-ylamino)imidazo[1,2-b]pyridazin-3-yl)benzonitrile
b 3-(4-chlorophenyl)-N-(pyridin-3-ylmethyl)pyrazolo[1,5-a]pyrimidin-5-amine
c 4-(6-(tetrahydro-2H-pyran-4-ylamino)imidazo[1,2-b]pyridazin-3-yl)benzonitrile
d 4-amino-1-tert-butyl-3-(10-naphthylmethyl)pyrazolo[3,4-d]pyrimidine
e 4-amino-1-tert-butyl-3-(10-naphthyl)pyrazolo[3,4-d]pyrimidine
f 4-Amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine
g Not determined.
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The Structure of PFPK7heterocyclic ring is sandwiched within the cleft and makes
a number of van der Waals and hydrophobic contacts with
Leu34 and Leu179. At the back of the cleft, the benzonitrile group
is sandwiched between Leu101 and Ile42 and makes a favorable
aromatic edge-face interaction with the side chain of Tyr117.
This interaction may be enhanced by potential dipolar interac-
tions induced between the inhibitor nitrile moiety and the
hydroxyl group of the side chain of Tyr117. The residue located
at the position of PFPK7 Tyr117 has been termed the ‘‘gate-
keeper’’ residue as it controls access to a hydrophobic pocket
behind the ATP binding site cleft. This hydrophobic pocket is
accessible to ATP-competitive inhibitors or ATP derivatives
(e.g., N6-benzyl-ATP) if the gatekeeper residue is small (Bishop
et al., 2000). The PFPK7-K510 structure suggests that although
the gatekeeper residue is a tyrosine, the pocket may still be
exploited by groups substituted at the para-position of the
K510 benzyl ring (Figure 3B).
The isopropyl and hydroxyl groups that emanate from the
K510 pyridazine ring occupy the ATP ribose-binding site
(Figure 3C). A comparison of the PFPK7-K510 and -AMPPNP
complexes (Figure S1) shows that the K510 hydroxyl group is
effectively located between the 20 and 30 ATP ribose hydroxyls
and is too distant to form hydrogen bonds with their ligands,
the side chain of Asp123 and the backbone carbonyl of
Ser176. However, the isopropyl group is oriented toward the gly-
cine-rich loop and is, in shape and character, complementary to
the PFPK7 molecular surface generated by the side chains of
Ile43, Leu34, and Asn35 (Figure 3C).
Figure 3. The PFPK7-K510 Complex
Structure
(A) K510 binding within the PFPK7 ATP binding
site. Stereo pair. The refined 2Fo-Fc electron den-
sity for bound K510 is contoured at 0.2 e $ A˚3,
which is equivalent to 1.3s. Residues referred to
in the text are drawn as ball and stick.
(B) The PFPK7 hydrophobic pocket. The view is
taken sliced through the PFPK7 fold in which the
molecular surface is colored by atom type with
carbons of PFPK7 in orange. K510 is drawn in
ball-and-stick mode with carbon atoms colored
magenta. The structure suggests that appropriate
substitutions at the para-position of the inhibitor
benzyl ring would probe the hydrophobic pocket.
Residues that compose the hydrophobic pocket
include Phe191, Cys103, and Ile92.
(C) The PFPK7 structure in the vicinity of the hinge
sequence. The PFPK7 backbone folds toward the
ATP binding site following the hinge sequence.
Asp123 protrudes to occlude access to the sur-
face of the C-terminal domain for inhibitors bound
within the ATP binding site.
When aligned with CDK2, PFPK7 has an
additional amino acid in the sequence be-
tween the hinge residue that makes a hy-
drogen bond with ATP N1 (Leu83 in
CDK2) and the conserved aspartate that
coordinates to the ribose 20-hydroxyl
group (Asp86 in CDK2). As a result,
PFPK7 Ser124 is found to overlay with Asp86 in CDK2, and
PFPK7 Asp123 protrudes to block access to the surface of the
C-terminal domain from the ATP binding site cleft (Figure 3C).
A similar feature results from an amino acid insertion in the
AURORA-2 sequence following the hinge and here also it creates
a smaller ATP-binding pocket in the kinase hinge region (Chee-
tham et al., 2002). Thus Asp123 represents a structural impedi-
ment to the binding of any inhibitor that either exploits the surface
of the C-terminal domain through pendant groups or, because of
its size, extends out from the ATP binding pocket. One of these
explanations accounts for the inactivity of known potent protein
kinase inhibitors toward PFPK7 (Dorin et al., 2005).
DISCUSSION
The structure of PFPK7 is, to our knowledge, the first of a protein
kinase from Plasmodium falciparum in its catalytically active
conformation and, as such, provides valuable insight into the
extent to which the protein kinase catalytic domain has been
conserved over considerable evolutionary distance. Many
features of the fold are conserved, but notably, the interactions
that stabilize the activation loop are novel. To our knowledge,
this is the first kinase for which a positively charged residue
has been found to be structurally equivalent to the phosphory-
lated activation loop residue that is a conserved feature of
most higher eukaryotic protein kinases.
A characteristic of P. falciparum proteins is the prevalence of
low-complexity sequences inserted into protein domains. The
234 Structure 16, 228–238, February 2008 ª2008 Elsevier Ltd All rights reserved
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The Structure of PFPK7Table 2. Crystallographic Data and Refinement Statistics
Data Collection
SeMet PFPK7 + AMPPNP;
MAD (Se)
PFPK7 + AMPPNP;
Native
PFPK7 + AMPPNP;
SAD (S) PFPK7 + K510
PFPK7 +
Hymenialdisine
Wavelength
(A˚)/beamline
0.9791
(peak)
ID29
0.9792
(inflection)
ID29
0.9686
(high
energy
remote)
ID29
0.9762 BM14 1.7710
BM14
0.9330
ID14-EH-2
0.9310
ID14-EH-3
Maximal resolution (A˚) 3.15 3.20 3.30 2.60 3.30 2.80 2.90
Cell dimensions (A˚) 73.5 73.5 73.5 72.5 73.2 73.4 73.1
82.3 82.2 82.2 81.8 82.4 82.0 82.5
138.9 138.9 138.9 138.2 137.9 138.9 138.7
Space group C2221 C2221 C2221 C2221 C2221 C2221 C2221
Observations 50,384 47,861 43,316 86,719 202,185 40,900 34,719
Unique reflections 7,495 7,154 6,533 13,019 6,570 10,971 9,580
Completeness (%) 99.2
(99.2)
99.3
(99.4)
99.3
(99.2)
100 (100) 100 (100) 97.7 (87.3) 99.7 (100.0)
Anomalous
completeness (%)
99.3 99.4 99.5 100
Rsym
a 0.087
(0.514)
0.088
(0.526)
0.083
(0.466)
0.050 (0.424) 0.100 (0.385) 0.066 (0.461) 0.096 (0.478)
Mean I/s(I) 17.9 (3.6) 18.0 (3.7) 17.9 (4.0) 24.1 (4.9) 40.6 (8.6) 15.8 (2.1) 11.0 (2.7)
Average multiplicity 6.7 6.7 6.6 6.7 30.8 3.7 3.6
Average
anomalous multiplicity
3.6 3.6 3.6 16.6
MAD/SAD Analysis
Phasing power acentric 1.569 1.864 1.224
FOM acentric/centric 0.46338/0.33052
Refinement
Resolution range (A˚) 20.00–2.60 20.00–2.75 20.00–2.90
Rconv
b 0.258 0.219 0.230
Rfree
c 0.327 0.296 0.316
Rsmd bonds
(A˚)/angles ()
0.010/1.349 0.009/1.309 0.009/1.375
Protein residues 4–279; 288–343 4–279; 288–343 4–279; 288–343
Other atoms 27 water molecules;
1 AMPPNP; 1 Mn2+
55 water
molecules;
1 K510 inhibitor
36 water
molecules;
1 hymenialdisine
Residues in
Ramachandran
allowed and
generously
allowed regions (%)
98.7 98.7 99.1
Mean protein
temperature factors (A˚2)
43.2 38.7 36.1
Mean water
temperature factors (A˚2)
45.6 47.3 35.7
Mean ligand
temperature factors (A˚2)
68.6 37.8 55.2
PDB accession code 2PML 2PMN 2PMO
a Rsym =
P
h
P
j
jIh; j  hIhij=
P
h
P
j
Ih; j where Ih,j is the intensity of the jth observation of unique reflection h.
b Rconv =
P
h
jjFohj  jFchjj=
P
h
jFohj where Foh and Fch are the observed and calculated structure factor amplitudes for reflection h.
c Rfree is equivalent to Rconv but is calculated by using a 5% disjoint set of reflections excluded from the maximum likelihood refinement stages.
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The Structure of PFPK7PFPK7 structure illustrates how these can be accommodated
and can form structured elaborations to a fold. Whether these
elaborations provide particular functionality to the kinase
domains in which they are found remains unclear, but the struc-
ture has allowed us to design mutations that produce molecules
that lack the inserted regions and to demonstrate that they show
equivalent levels of autophosphorylation to the wild-type en-
zyme. We aim to establish whether these mutants can function-
ally complement the full-length protein and whether the inserted
sequences are important for PFPK7 activity toward in vivo
substrates as part of our on-going structure-function studies.
An arrayed peptide library was used to identify PFPK7 se-
quence preferences around the site of phosphotransfer and
revealed the enzyme’s strong preference for positively charged
residues. This result is supported by the structural study that
revealed an active site cleft with overall negative character. The
sequence and structure of peptide recognition sites have shown
promise as indicators of possible in vivo substrates in yeast and,
in a similar way, this structure will contribute to the on-going chal-
lenge of fitting this orphan kinase into a physiological pathway.
The functional significance (if any) of PFPK7 autophosphoryla-
tion is yet to be elaborated. Regulation of activity by autophos-
phorylation in trans within the kinase domain at sites that are
not within the activation loop has only recently been reported
as a potential mechanism for regulation of catalytic activity in
protein kinases of higher eukaryotes. For example, AKT is auto-
phosphorylated in trans at Ser246 subsequent to kinase activa-
tion following phosphorylation of Thr308 (within the activation
loop) and Ser473 by upstream kinases (Li et al., 2006). In addition
to PFPK7, autophosphorylation of P. falciparum kinases within
the catalytic domain has also been reported for PFPK5 (Le
Roch et al., 2000) and PFMRK (Chen et al., 2006), suggesting
that this may be a widely employed mechanism in P. falciparum
to regulate kinase activity. Further experiments to identify the in
vitro PFPK7 phosphorylation sites and to establish whether it au-
tophosphorylates in vivo are in progress.
The structures of the PFPK7-K510 and PFPK7-hymenialdisine
(Figure S5) complexes are, to our knowledge, the first to elabo-
rate at atomic resolution the interactions that can be exploited
to generate potent ATP-competitive PFPK7 inhibitors. Taken
together with the results of the thermal stability assay, these
structures begin to outline the structure-activity relationship of
PFPK7 inhibition that can be further refined by inclusion of struc-
tures for PFPK7 bound to other hits. The compounds identified to
date reveal features that can be developed into a pharmacophore
model to provide a starting point for inhibitor design by interactive
graphics visualization and virtual screening. Potent and selec-
tive PFPK7 inhibitors would be useful reagents to help dissect
PFPK7’s biological activities. Furthermore, as disruption of
PFPK7 expression has been shown to slow the asexual growth
of P. falciparum (Dorin-Semblat et al., 2008), PFPK7 inhibitors
represent promising leads for antimalarial drug discovery.
EXPERIMENTAL PROCEDURES
Protein Expression, Purification, and Crystallization
The full-length PFPK7 sequence (residues 1–343) cloned into the vector
pGEX6P-1 (GE Healthcare, UK) was optimally expressed in BL21-CodonPlus
(RIL) cells (Stratagene, CA) and purified from the soluble fraction by sequential236 Structure 16, 228–238, February 2008 ª2008 Elsevier Ltd All rigaffinity and size-exclusion chromatography. Seleno-methionine derivatives
were prepared by expressing the protein in E. coli strain B834(DE3) (Novagen,
WI), grown in minimal media supplemented with Se-Methionine (Molecular
Dimensions, UK). PFPK7-AMPPNP crystals were grown at 25C by using
the sitting drop method by mixing equal volumes (1 ml) of PFPK7 (9 mg/ml sup-
plemented with 3 mM AMPPNP) and well solution (0.1 M HEPES [pH 7.5], 20%
PEG 10K). PFPK7-inhibitor cocrystallization trials were set up after incubation
of the protein solution with 0.4 mM K510 or 3 mM hymenialdisine (both in 100%
DMSO) for 20 min on ice or 15 min at room temperature, respectively. After
incubation, the protein-inhibitor mixture was filtered through a 0.22 mm filter
unit (Millipore, UK). Crystals were cryo-protected by soaking briefly in mother
liquor supplemented with 35% PEG 200 before flash freezing in liquid nitrogen
at 77 K. PFRAB11B (EMBL accession AJ879563.1) cloned into pMTC3 was
expressed in BL21 cells and purified from inclusion bodies following urea
solubilization and a single affinity chromatography step on Ni-NTA. Further
details of the protein purification procedures are provided in the Supplemental
Experimental Procedures.
Site-Directed Mutagenesis
PFPK7 mutants were generated by the overlap extension PCR method
(Ho et al., 1989) and the pGEX6P-1-PFPK7 wild-type plasmid as the template.
Kinase Assays
Kinase reactions to measure PFPK7 autophosphorylation and activity toward
myelin basic protein were performed by using 500 ng of recombinant PFPK7 in
a total volume of 30 ml as described (Dorin et al., 2001), (Dorin et al., 2005).
PFPK7 activity toward kinase-dead PFPK7 (the K55M mutant) was measured
in 30 ml of kinase buffer (20 mM Tris [pH 7.5], 20 mM MgCl2, 2 mM MnCl2) by
using 1 mg of GST-wild-type PFPK7 and 500 ng of PFPK7 K55M. PFPK7
activity toward PFRAB11B was measured essentially as described (Dorin
et al., 2001), although the buffer was modified by addition of 2 M urea. Quan-
tification of GST-PFPK7 autophosphorylation for determination of IC50 values
was carried out as described in (Dorin et al., 2001), and the amount of precip-
itable radiolabel incorporated into protein was measured by phosphorimaging
(Typhoon 9400, GE Healthcare, UK). The DMSO concentration (10%) was kept
constant in all reactions. For comparing the autophosphorylation of mutant
S167A to that of wild-type PFPK7, measurements of autophosphorylation
were taken in duplicate, and results were normalized to that of wild-type
PFPK7 activity (100%). Limits of the error bars in Figure S3B correspond to
the higher and lower values observed in the duplicate measurements. Kinase
activity toward a peptide substrate library (Pepscan Systems B.V., Holland)
was determined following the manufacturer’s instructions and measured by
phosphorimaging (Fuji FLA-3000, Stamford, CT). A consensus substrate phos-
phorylation sequence was compiled by using a scoring matrix based on an
alignment of the best substrates for PFPK7 as determined by PepChip Kinase
analysis. Further details of the consensus determination are provided in the
Supplemental Experimental Procedures.
Thermal Stability Measurements
Thermal melting experiments were carried out by using a Mx3005p real-time
PCR machine (Stratagene, CA) essentially as described in Matulis et al.
(2005) and Bullock et al. (2005). Full details are provided in Supplemental
Experimental Procedures.
Parasite Culture and Hypoxanthine Incorporation Assay
P. falciparum (clone 3D7) was grown in human erythrocytes as described
previously (Walliker et al., 1987), except for the replacement of human serum
with 0.5% Albumax. The effect of inhibitors PP2, 1NA-PP1, 1NM-PP1 (Calbio-
chem, UK), and K497, K510, and K109 (BioFocus, UK) on parasite growth was
measured by using the hypoxanthine incorporation assay described by
Desjardins et al., (1979) and adapted by Harmse et al., (2001), with a total
48 hr assay time. Error bars correspond to the SEM (standard error of the
mean) from three separate experiments.
X-Ray Crystallography Data Collection and Processing
All crystals were cryo-protected in the crystallization solution supplemented
with 35% PEG 200 and were flash cooled in liquid nitrogen prior to data collec-
tion. The diffraction data were collected at 100 K on prefrozen crystals. Thehts reserved
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The Structure of PFPK7best orientation of the crystals to achieve highest completeness with the low-
est data collection time was determined with the program STRATEGY (Leslie,
1992). All collected data were integrated in MOSFLM (Leslie, 1992) and scaled
with SCALA (CCP4, 1994). The rest of the structure factor calculations were
performed with programs supported by CCP4 (CCP4, 1994) unless otherwise
specified. The crystals belong to the space group C2221 and contain one
molecule per asymmetric unit with a solvent content of 53%. Data collection
statistics are given in Table 2.
Structure Solution and Refinement
Initially, we attempted to determine the PFPK7 structure by molecular replace-
ment. The same weak molecular replacement solution came back recurrently
in different molecular replacement programs by using the rat TAO2 kinase
domain (PDB ID: 1U5R). However, the phases derived from this solution
were found to be unsatisfactory as large regions of the PFPK7 fold were badly
defined, precluding a confident structure determination. As a result, we pre-
pared Se-Met-PFPK7 crystals and attempted to solve the structure with a non-
optimal Se-SAD dataset collected at l = 0.933 A˚. This method did not yield
a structure with refinement statistics as good as we would have anticipated
from a 2.6 A˚ dataset in which most of residues had been located in the resulting
electron density map. Consequently the structure of PFPK7 was solved by the
multiwavelength anomalous dispersion method (MAD) at the selenium edge.
Experimental phases were obtained by using a three-wavelength experiment
with a selenomethionine derivative of PFPK7. Using data to a maximal resolu-
tion of 3.7 A˚, the six selenium sites, expected on the basis of the PFPK7
sequence, were clearly found and initial phases were calculated in SHELX
(Sheldrick, 1990). Refinement of the six selenium positions and density modi-
fication by solvent flattening were performed in SHARP (La Fortelle and
Bricogne, 1997). Phase extension to 2.6 A˚ was performed in DM (Cowtan,
1994) with the native data set of PFPK7 cocrystallized in the presence of
AMPPNP. The electron density map supports the presence of a bound
AMPPNP molecule within the ATP binding site. The initial model was built in
the experimental electron density map with O (Jones et al., 1991) and sub-
jected to rigid body refinement, followed by restrained refinement in REFMAC5
(CCP4, 1994). Alternate cycles of rebuilding in O, restrained refinement in
REFMAC5, and addition of water and solvent molecules in Coot (Emsley and
Cowtan, 2004) resulted in a final model containing 340 amino acids, 27 water
molecules, 1 AMPPNP molecule, and 1 manganese molecule with an R factor
of 0.258 (Rfree 0.327). In the Ramachandran plot, 98.7% of all residues are in
the allowed or generously allowed regions. A more detailed description of
the structure solution and refinement and a statistical summary are presented
in the Supplemental Data.
The structures of PFPK7 in complex with the inhibitors K510 and hymenial-
disine (Figure S5) were determined by molecular replacement with MOLREP
(CCP4, 1994) using the native PFPK7 structure and the PFPK7-K510 structure,
respectively, as the search model (without AMPPNP or the inhibitor K510 and
solvent molecules). Cycles of rigid body and restrained refinement in
REFMAC5 against the PFPK7-K510 and PFPK7-hymenialdisine data pro-
duced difference electron density maps that each featured strong positive
difference density at the ATP binding site, consistent with the presence of,
respectively, bound K510 and hymenialdisine. Alternate cycles of rebuilding
and refinement led to a final model for the PFPK7-K510 complex comprising
340 amino acids and a crystallographic R factor of 0.219 and Rfree of 0.296.
The final PFPK7-hymenialdisine model includes 340 residues and has a crys-
tallographic R factor of 0.230 and Rfree of 0.316. A summary of the refinement
statistics is presented in Table 2.
Supplemental Data
Supplemental Data include details of the PFPK7-hymenialdisine complex and
of the PFPK7 structure refinement, Supplemental Experimental Procedures,
and five figures, and can be found with this article online at http://www.
structure.org/cgi/content/full/16/2/228/DC1/.
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